Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

7.38
-0.0400-0.54%
Post-market: 7.30-0.0800-1.08%19:59 EDT
Volume:4.31M
Turnover:31.97M
Market Cap:2.73B
PE:-3.46
High:7.45
Open:7.41
Low:7.38
Close:7.42
52wk High:7.45
52wk Low:3.27
Shares:369.95M
Float Shares:294.14M
Volume Ratio:0.51
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1359
EPS(LYR):-2.9137
ROE:-417.21%
ROA:-39.03%
PB:15.48
PE(LYR):-2.53

Loading ...

EXPLAINER-What to know about psychedelic therapies cited by Trump

Reuters
·
Apr 22

Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health

Dow Jones
·
Apr 21

NASD Most Active Issues

Dow Jones
·
Apr 21

H.C. Wainwright Reaffirms Their Buy Rating on Atai Beckley N.V. (ATAI)

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

AtaiBeckley Up Over 28%, On Pace For Record Percent Increase -- Data Talk

Dow Jones
·
Apr 20

Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

Benzinga Earnings
·
Apr 20

ATAI Life Sciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 20

BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen

Reuters
·
Apr 20

Berenberg Raises Price Target on AtaiBeckley to $14 From $13, Keeps Buy Rating

MT Newswires Live
·
Apr 20

Psychedelic Drug Developers Rise Premarket After Trump Orders FDA to Expedite Reviews

THOMSON REUTERS
·
Apr 20

Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%

THOMSON REUTERS
·
Apr 20

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

ATAI Life Sciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 17

BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research

Reuters
·
Apr 17

Atai Beckley CEO joins Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 14

AtaiBeckley says BPL-003 hits 67% Day-2 response in Phase 2a TRD study

Reuters
·
Apr 08

Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide?

Simply Wall St.
·
Mar 30

Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)?

Simply Wall St.
·
Mar 28

ATAI Life Sciences Initiated at Buy by Deutsche Bank

Dow Jones
·
Mar 27